Busy. Please wait.
or

show password
Forgot Password?

Don't have an account?  Sign up 
or

Username is available taken
show password

why


Make sure to remember your password. If you forget it there is no way for StudyStack to send you a reset link. You would need to create a new account.
We do not share your email address with others. It is only used to allow you to reset your password. For details read our Privacy Policy and Terms of Service.


Already a StudyStack user? Log In

Reset Password
Enter the associated with your account, and we'll email you a link to reset your password.

Remove ads
Don't know
Know
remaining cards
Save
0:01
To flip the current card, click it or press the Spacebar key.  To move the current card to one of the three colored boxes, click on the box.  You may also press the UP ARROW key to move the card to the "Know" box, the DOWN ARROW key to move the card to the "Don't know" box, or the RIGHT ARROW key to move the card to the Remaining box.  You may also click on the card displayed in any of the three boxes to bring that card back to the center.

Pass complete!

"Know" box contains:
Time elapsed:
Retries:
restart all cards




share
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.

  Normal Size     Small Size show me how

hemostatic disorders

handbook

QuestionAnswer
Clinical effects of Factor XII deficiency none
Describe the clinical bleeding associated with von Willebrand's disease mucosal bleeding(epistaxis, menorrhagia, GI bleed), excessive bruising, or bleeding after minor trauma
Describe the clinical bleeding associated with platelet disorders mucosal bleeding(epistaxis, menorrhagia, GI bleed), excessive bruising, or bleeding after minor trauma
Describe the bleeding associated with hemophilia Bleeding into joints, muscles or soft tissues
The most common causes of primary fibrinolysis Severe liver disease and hepatic surgery
In non-bleeding patients with thrombocytopenia caused by marrow failure, prophylactic platelet transfusions are generally reserved for platelet counts less than this number 10K
This syndrome is due to deficiency of GPIb/IX in platelets Bernard-Soulier
This syndrome is due to deficiency of GPIIb/IIIa in platelets Glanzmann thrombasthenaa
This drug has been effective treating bleeding associated with uremia DDAVP(desmopressin)
Describe the underlying pathophysiology of the most common type of von Willebrand's disease Type 1 vWD has mild to moderate quantitative deficiency of vWF
In this type of von Willebrand's disease, vWF is virtually absent along with Factor VIII Type 3 vWD
These lysine analogues are used as anti-fibrinolytics epsilon aminocaproic acid and tranexamic acid)
Mechanism of action of tranexamic acid and epsilon aminocaproic acid interfere with plasmin binding to fibrin, thereby inhibiting fibrinolysis (anti-fibrinolytics)
This site of bleeding is a contraindicationto tranexamic acid and EACA upper urinary tract bc obstruction may result from failure of clot lysis
X-linked congenital bleeding disorder caused by Factor VIII deficiency Hemophilia A
Products of choice in Hemophilia A Recombinant Factor VIII
FDA requires that each unit of cryoprecipitated AHF contain this much factor VIII 80 IU
DDAVP and cryo can be useful in the treatment of: A. Hemophilia A B. Hemophilia B C. Both D. Neither A.
What is the mainstay of therapy for hemophilia patients with inhibitors to factor VIII or IX? activated Prothrombin complex concentrates (aPCC) or recombinant Factor VIIa (rFVIIa)
Treatment of choice for Factor V deficiency plasma
Treatment for Factor XII deficiency none
This deficiency is associated with umbilical stump bleeding Factor XIII
Treatment for alpha2-plasmin inhibitor deficiency epsilon aminocaproic acid (EACA)
Vitamin K dependent coagulation factors II,VII,IX, X
Warfarin-induced skin necrosis is related to the drug's early effect on this protein C synthesis
If patient has serious bleeding on warfarin, this product is recommended 4-factor (II,VII,IX,X) Prothrombin complex concentrate (PCC)
Calculation for FFP units needed to reverse heparin effect plasma is not effective in reversing heparin effect
Drug used to reverse heparin effect protamine sulfate
This drug is a synthetic pentasaccharide that strongly binds anti-thrombin and acts as a selective inhibitor to Factor Xa Fondaparinux
This drug is an oral targeted thrombin inhibitor Dabigatran (Pradaxa)
These drugs are oral targeted Factor Xa inhibitors Rivaroxaban (Xarelto) and Apixaban (Eliquis)
These drugs selectively inhibit ADP-induced activation of platelets via irreversible alteration of the platelet P2Y12 receptor Clopigrodel (Plavix) and Prasugrel (Effient)
This is a synthetic analogue of vasopressin DDAVP
These factors are released from endothelial cells when DDAVP is given vWF, Factor VIII, and tPA
These antifibrinolytic drugs are synthetic analogues of lysine EACA and Tranexamic acid
Mechanism of action of tranexamic acid occupies lysine binding sites of plasminogen and plasminogen activators which delays clot resorption
This is the most important protease inhibitor of activated coagulation factors and is central to the in-vivo effect of heparin antithrombin
Condition in infants with homozygous deficiency of protein C or S purpura fulminans
When does "warfarin induced skin necrosis occur"? When patients with protein C or S deficiency are started on warfarin
This is the specific antibody epitope in anti-phospholipid syndrome beta-2 glycoprotein I
Clinical effect of "Lupus anti-coagulant" thrombosis
Lab criteria for Lupus anticoagulant 1. prolonged PTT 2. prolonged Russell viper venom test 3. fails to correct on 1:1 mixing study 4. corrects when excess phospholipid is added
This is a drug associated ITP disorder characterized by paradoxical thrombosis HIT: heparin induced thrombocytopenia
These tests are used to confirm a dx of HIT antibodies to platelet factor 4/heparin complexes or serotonin release assay
Platelet dose for a patient with HIT and a platelet count of 19,000 none. avoid platelet transfusion in this dx
The majority of adult-onset cases of TTP have a deficiency of this protein ADAMTS13
Outline treatment of TTP if TPE is not readily available FFP at 40ml/kg until TPE can be arranged
Etiology of Typical hemolytic uremic syndrome (HUS) shiga toxin producing E. coli
Best treatment for atypical HUS eculizamab, C5 monoclonal antibody, disease results from excessive activation of alternative complement pathway
Created by: jfshikle